BNET Industries
Market Cap:$143.3B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
News & Analysis
Filter by
mergers & acquisitions and pfizer inc. - All News and Analysis
Pfizer Scientist Stabbed Wife After Job Loss, Police Say
BNET
- 2009-11-18
A former Pfizer PFE employee who lost his job and “was convinced he could not provide for his family any further,†has been charged with stabbing his wife, according to police. Pfizer is in the process of laying off 19,500 employees in its merger with Wyeth. Asbill was involved in...
As Tax Breaks for Pfizer End, Jobs Disappear
BNET
- 2009-11-16
As Pfizer PFE reorganizes after its merger with Wyeth, municipalities are finding that the tax deals they once struck to keep the drug giant in town are having short-term advantages at best and, at worst, no effect at all. Pfizer must make 19,500 layoffs across its empire to make the...
Pfizer's R&D Cuts Render Kelo v. New London Eminent Domain Case a Waste of Time
BNET
- 2009-11-10
Pfizer PFE will close its New London, Conn., site and consolidate operations there at the nearby Groton, Conn., site in a swathe of R&D closures as the company seeks 19,500 job cuts in the wake of its merger with Wyeth. Pfizer's abandonment of its plans for New London render moot...
Pfizer Aiming for 30,900 Layoffs Through 2012
BNET
- 2009-11-06
Pfizer has laid off 26,300 employees since 2005, and hopes eventually to lay off a total of 30,900 through 2012, according to its 10-Q filing with the SEC. The company had several rounds of layoffs before its acquisition of Wyeth in an attempt to get $6 billion in annual savings...
Pfizer Unveils Shiny New "Leaping" Logo
BNET
- 2009-11-05
Pfizer PFE, fresh from consummating its merger with Wyeth WYE, has unveiled a new logo. Don't get too excited -- it looks a lot like the old logo. by Jim Edwards
Pfizer Q3: Healthy Profit Masks Revenue Decline
BNET
- 2009-10-20
This merger with Wyeth can't come soon enough for Pfizer. The company's revenues were down 3 percent to $11.6 billion in Q3 2009, although net income was $2.8 billion up 26 percent. That healthy profit growth masks the reality of Pfizer's business: Of all its drugs, only four saw growth....
Pfizer Closes Bridgewater Site; Clock Ticks on CT Tax Deal; Layoffs All Over
BNET
- 2009-10-15
As Pfizer decides how to cut 19,500 jobs in its merger with Wyeth, which closed today, the clock is ticking at its New London campus on a tax deal that gives the company an 80 percent reduction in its municipal bill. by Jim Edwards
Pfizer's Silence on Post-Wyeth Merger Job Cuts, Site Closures Has Everyone on Edge
BNET
- 2009-10-09
Pfizer is driving everyone nuts with its silence on which sites, offices and labs it will close following its merger with Wyeth. Even the Connecticut governor doesn't know what Pfizer's plans will be, even though the state has two sites -- Groton and New London -- and 5,000 jobs at...
In Pfizer-Wyeth Merger Suit, It's Capitalism v. Socialism
BNET
- 2009-08-25
The suit filed by various pharmacies to block the Pfizer-Wyeth merger is worth reading if you want to put in context the sheer size of the merger. It also delineates a faux conflict between the forces of capitalism pharmacies and socialism drug companies. by Jim Edwards
Pfizer Offered $53 a Share for Wyeth; Wyeth Failed to Say Yes
BNET
- 2009-06-19
Wyeth rejected an offer from Pfizer at $53 a share, according to a Wyeth proxy statement filed yesterday. Pfizer eventually acquired Wyeth for $50.33 a share. Wyeth's failure to say yes to Pfizer's highest offer comes in the company's explanation of how it was acquired, filed as part of the...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
Presented by the Premiere Rewards Gold Card from American Express